More significantly, our cell viability results demonstrate that the further overexpression of PRMT5 in the KRAS mutant CRC cells affected a further 2.4-fold (p < 0.005) and 2.0-fold (p < 0.005) decrease in cell viability after 60 h of treatment with 1 μM & 10 μM PRMT5 inhibitor concentrations, respectively, when compared to the KRAS WT CRC cells (Figure 4). This evidence concerns the gene KRAS and colorectal carcinoma.